Mon panier

APC-Labeled Human Siglec-3 / CD33 Protein, His TagStar Staining

Numéro de produit/spécification
Prix
Qté
CD3-HA2H3-25tests
$360.00
CD3-HA2H3-200tests
$2245.00
ETA of in-stock products:2 business days
Total des articles Montant du produit$ 0

Détails du produit

  • Synonyms

    CD33, SIGLEC3, gp67

  • Source

    APC-Labeled Human Siglec-3 Protein, His Tag (CD3-HA2H3) is produced via conjugation of APC to Human Siglec-3 Protein, His Tag with a new generation site-specific technology under Star Staining labeling platform. Human Siglec-3 Protein, His Tag is expressed from human 293 cells (HEK293). It contains AA Asp 18 - His 259 (Accession # AAH28152.1).

    Predicted N-terminus: Asp 18

    Request for sequence

  • Molecular Characterization

    Siglec-3 Structure

    Other Tags and Version Biotin & Other Labeled Version

    This protein carries a polyhistidine tag at the C-terminus.

  • Conjugate

    APC

    Excitation Wavelength: 640 nm

    Emission Wavelength: 661 nm

  • Purity

    >90% as determined by SDS-PAGE.

  • Formulation

    Lyophilized from 0.22 μm filtered solution in PBS, 0.2% BSA, pH7.4 with trehalose as protectant.

    Contact us for customized product form or formulation.

  • Reconstitution

    Please see Certificate of Analysis for specific instructions.

    For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

  • Shipping and Storage

    This product is shipped at ambient temperature.

    For long term storage, the product should be stored at lyophilized state at -20°C or lower.

    Please protect from light and avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. -20°C to -70°C for 12 months in lyophilized state;
    2. -70°C for 3 months under sterile conditions after reconstitution.
  • ACRO Quality Management System

    1. QMS(ISO, GMP)
    2. Quality Advantages
    3. Quality Control Process

Les clients ont également consulté

Affichage des données

  • Evaluation of CAR expression

    FACS Analysis of Anti-EGFRvIII CAR Expression

     Siglec-3 CAR_T

    5e5 of anti-Siglec-3 CAR-293 cells were stained with 100 μL of 1:50 dilution (2 μL stock solution in 100 μL FACS buffer) of APC-Labeled Human Siglec-3 Protein, His Tag (Cat. No. CD3-HA2H3) and negative control protein respectively (Fig. C and B), and non-transfected 293 cells were used as a control (Fig. A). APC signal was used to evaluate the binding activity (QC tested).

    Protocol
  • FACS Analysis of Non-specific binding to PBMCs

     Siglec-3 CAR_T

    5e5 of PBMCs were stained with APC-Labeled Human Siglec-3 Protein, His Tag (Cat. No. CD3-HA2H3) and anti-CD3 antibody, washed and then analyzed with FACS. FITC signal was used to evaluate the expression of CD3+ T cells in PBMCs, and APC signal was used to evaluate the non-specific binding activity to PBMCs (QC tested).

    Protocol

Avis des utilisateurs
Publier un commentaire

Introduction de fond

Myeloid cell surface antigen CD33 is also known as SIGLEC3, Siglecs (sialic acid binding Ig­like lectins) and GP67, is a single-pass type I membrane protein which belongs to the immunoglobulin superfamily and SIGLEC (sialic acid binding Ig-like lectin) family. Human CD33 / Siglec-3 cDNA encodes a 364 amino acid (aa) polypeptide with a hydrophobic signal peptide, an N-­terminal Ig-­like V­-type domain, one Ig­-like C2-­type domains, a transmembrane region and a cytoplasmic tail. CD33 / Siglec-3 usually considered myeloid-specific, but it can also be found on some lymphoid cells. In the immune response, CD33 / Siglec-3 may act as an inhibitory receptor upon ligand induced tyrosine phosphorylation by recruiting cytoplasmic phosphatase(s) via their SH2 domain(s) that block signal transduction through dephosphorylation of signaling molecules. CD33 / Siglec-3 induces apoptosis in acute myeloid leukemia.

Progrès de frontière

 
Progrès du développement médicamenteux
  • Nom anglais:

    Myeloid cell surface antigen CD33

  • Catégorie:

  • Nombre de médicaments répertoriés:

    1 Détails

  • Nombre de médicaments cliniques:

    44 Détails

  • Étape de développement la plus élevée:

    Approved

Drug Candidate Licensing
More
  • Informations de base sur le produit
  • Détails du produit
  • Les clients ont également consulté
  • Affichage des données
  • Avis des utilisateurs
  • Contexte